Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

(marketscreener.com) At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 demonstrated encouraging 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum resistant ovarian cancer and was well tolerated, with all responders remaining on therapyLonger follow up data will be included in the posters available...https://www.marketscreener.com/quote/stock/COMPUGEN-LTD-8758/news/Compugen-s-COM701-anti-PVRIG-in-Dual-and-Triple-Combination-Demonstrates-Preliminary-Anti-Tumor-Ac-42452619/?utm_medium=RSS&utm_content=20221201